With rapid growth of SHL Group and along with new innovations and technologies developed for pen and auto injectors, the Taoyuan facility requires expansion of space, and thus will be relocating to a the new site in Nankan, Taoyuan. Construction started in Q4 of 2015 and completion of the building is expected to be in Q4 of 2017.
In Q1 2018, all administrative offices and parts of the production will be relocated to the new site. The ground level has 12,349 m2 area of space, to which a 7-stories high office-and manufacturing building with 62,603 m2 total floor space is to be built on. The new facility will help SHL Group increase production capacity, improve efficiency and raise overall manufacturing quality. This step will open new opportunities for implementing the latest manufacturing technologies.
To mark this special event, the official groundbreaking is set to be on the morning of February 2nd, 2016. President of SHL Group Roger Samuelsson will be present, along with the SHL Group’s senior executives such as Managing Director of Taiwan, Ulrich Faessler; Managing Director of US, Peter Noolandi; Executive VP of Commercial Operations & Business Development, Mats Persson; VP of Research & Development, Frank Isaksson; Executive VP of SHL Ventures, Stefan Ahlquist; VP of Quality Assurance & Regulatory Affairs, Shelley Chew, and VP of Supply Chain & Business Excellence, Richard Koch.
According to a recent industry report, the auto injector market will reach USD 2.5 billion globally in 2020. Auto injectors have emerged as one of the fastest growing drug delivery solutions, driven by factors such as auto injectors’ ease of self-administration, allowance for at-home drug administration, decreased hospital visits (thereby reducing the cost of health care) and others. Commenting on this expansion, CEO & President of SHL Group, Roger Samuelsson states, “Customer needs has always been one of the top priorities of SHL Group. Every strategy that we make, we hope to exceed customer expectations. To meet the needs of a growing market for pen and auto injectors, we must constantly invest in more advanced equipment and expand our production capacity.” SHL Group keeps customer’s best interest at heart and with the expansion comes improved facility, products and services.
Groundbreaking Ceremony information:
Date: February 2nd, 2016 (Tue)
Place: No.44-1, Liufu Rd., Luzhu Dist., Taoyuan City 338, Taiwan (R.O.C.)
SHL is a world-leading solution provider in the design, development and manufacturing of advanced drug delivery devices such as auto injectors and pen injectors. With locations in Taiwan, Sweden and the US, our experienced engineers and designers develop product enhancements and breakthrough drug delivery solutions for pharma and biotech clients globally. Significant investment in R&D has enhanced our broad pipeline of “next-generation” drug delivery systems. These innovative devices include a range of disposable and reusable injectors with fixed or variable dosing, enhanced precision and the ability to accommodate high viscosities.
With over 3,700 staff worldwide, our organization consists of several distinct group companies:
SHL Medical designs, develops and manufactures advanced drug delivery devices, as well as provides final assembly, labeling and packaging services for leading pharmaceutical and biotech companies across the globe
SHL Healthcare develops and manufactures equipment solutions for home, hospital and long term care use
SHL Technologies provides contract manufacturing and engineering services for the production of complex medtech and industrial products
For additional information visit www.shl.group